SciNeuro, Novartis sign $1.7 billion licensing deal to develop Alzheimer's drugs

Core Viewpoint - Swiss drugmaker Novartis has entered into a licensing agreement valued at nearly $1.7 billion with privately held SciNeuro Pharmaceuticals to develop potential antibody treatments for Alzheimer's disease [1] Company Summary - Novartis is focusing on the development of innovative treatments for Alzheimer's disease through this significant licensing deal [1] - The collaboration with SciNeuro Pharmaceuticals indicates Novartis's commitment to addressing neurodegenerative diseases [1] Industry Summary - The deal highlights the growing interest and investment in Alzheimer's disease treatments within the biotechnology sector [1] - The licensing agreement reflects the potential market value and demand for effective therapies targeting Alzheimer's disease [1]